FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 769 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Research with Integrity – the madness of short methods December 7, 2022 Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer January 3, 2024 Medicare Open Enrollment is Almost Here-What You Need to Know for... October 13, 2020 Pruebas genéticas para el cáncer en familias: Preguntas y respuestas con... May 19, 2022 Load more HOT NEWS How to Strengthen Your Immune System: Part 2 New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma How will new cancer medicines be approved in the future? How to Tell If Cancer Information on Social Media Is “Fake...
